Table 2.

Comparison Between CAB-Sensitive and CAB-Resistant Patients

Characteristic	Sensitive (n = 135)	Resistant (n = 44)	Pa
Sex ratio, F/M	62/73	21/23	0.49
Age at diagnosis, y	38.2 ± 16.6	29.7 ± 13.6	0.13
	34.5 (10.6–79.0)	26.5 (13.3–68.6)
PRL level at diagnosis, ng/mL	1292 ± 2182	3174 ± 4972	<1.10−2
	534 (25–16,000)	1100 (130–22,700)
Maximal tumor diameter at diagnosis, mm	22.0 ± 10.3	30.7 ± 21.0	0.02
	20.2 (10.0–55.0)	23.0 (10.0–110.0)
Impaired vision	31 (23.0)	12 (27.3)	0.42
Invasion in cavernous sinus	46 (34.1)	21 (47.7)	0.44
Gonadotropic deficiency only	43 (31.9)	12 (27.3)	<1.10−2
AIP mutation	14 (10.4)	6 (13.6)	0.92
MEN1 mutation	2 (1.5)	3 (6.8)	0.24
Initial dose of CAB, mg/wk	0.73 ± 0.30	1.36 ± 0.86	<1.10−4
	0.50 (0.13–2.00)	1.00 (0.50–3.50)
CAB dose at time of PRL normalization, mg/wk	0.97 ± 0.50	3.81 ± 1.28	<1.10−4
	1.00 (0.25–3.00)	3.50 (2.50–8.00)
Duration of CAB treatment, y	5.8 ± 4.6	8.9 ± 4.7	<1.10−4
	5.1 (0.1–25.4)	9.0 (1.0–18.6)
Duration of follow-up, y	9.6 ± 8.3	13.2 ± 8.3	<1.10−2
	6.3 (0.0–37.3)	11.9 (1.2–35.0)
Time between CAB initiation and PRL normalization, y	1.5 ± 2.3	5.5 ± 4.1	<1.10−4
	0.6 (0.0–14.3)	4.3 (0.7–12.4)
Bromocriptine treatment	41 (30.4)	18 (40.9)	0.20
Quinagolide treatment	22 (16.3)	16 (36.4)	<1.10−2
Surgery	16 (11.9)	15 (34.1)	<1.10−2
Radiotherapy	3 (2.2)	6 (13.6)	0.37

Values are given as mean ± standard deviation, median, and range, or as numbers and percentages.

^aStatistical significance of comparison between males and females. Statistically significant differences are indicated in bold.